Journal
CLINICAL DRUG INVESTIGATION
Volume 37, Issue 2, Pages 167-174Publisher
ADIS INT LTD
DOI: 10.1007/s40261-016-0469-9
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81570106, 81570111, 81400088, 81400085]
- anticancer major special project of Tianjin [12ZCDZSY18000, 12ZCDZSY17900]
- Tianjin Municipal Natural Science Foundation [14JCYBJC25400, 15JCYBJC24300]
- Science and Technology Foundation of Tianjin Municipal Health Bureau [2011kz115]
- Tianjin Health and Family Planning Commision [15KG150]
Ask authors/readers for more resources
Background and Objectives The therapy in elderly patients with acute myeloid leukemia (AML) is a big challenge because of poor risk factors and inferior tolerance to intensive chemotherapy. This study aims to compare the efficacy between reduced-intensity idarubicin plus cytarabine and daunorubicin plus cytarabine (IA regimen and DA regimen, respectively) in elderly patients with newly diagnosed AML. Methods We retrospectively investigated 74 patients with newly diagnosed non-M3 AML aged > 60 years, where 33 patients received IA regimen, 30 patients received DA regimen, while 11 patients received supportive treatment. We observed the complete remission (CR) rates, overall survival (OS) and side effects in different arms. Results The CR rate in IA arm (70.4 %, 19/27) was significantly higher than that in DA arm (40 %, 10/25) in de novo AML (p = 0.028), and further significantly higher when white blood cell (WBC) count > 10 x 10(9)/L (p = 0.042) and ECOG (Eastern Cooperative Oncology Group) score < 2 (p = 0.021). The overall survival of the entire population was poor with a median survival of 10 months, 1- and 2-year survival rates were 40.5 % (30/74) and 9.5 % (7/74). The median survival of the patients with chemotherapy was 12 months, which was significantly longer than patients treated supportively (4 months) (p < 0.001). There were no differences of median survival and duration of CR between two arms. Early mortality decreased in the past 5 years in both groups. Meanwhile, low-dose idarubicin was well tolerated in elderly patients. Conclusions Reduced-intensity chemotherapy offered an improvement in survival, and the reduced-intensity IA regimen could improve CR rate in elderly patients with de novo AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available